On December 11, 2015 the Food and Drug Administration (FDA) approved alectinib (Alecensa®) for some patients with metastatic non-small cell lung cancer (NSCLC) with mutations in the ALK gene.
The agency granted an accelerated approval for alectinib for patients whose cancer is no longer responding to the ALK-targeted agent crizotinib (Xalkori®) or who are unable to tolerate further treatment with crizotinib because of side effects. Read more here.
No comments:
Post a Comment